Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease

Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease

Aim. To study the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, on lipid levels in patients who receive secondary prevention of cardiovascular diseases (CVD) and require enhanced lipid-lowering therapy.Material and methods. The study included 49 patients (ag...

Full description

Bibliographic Details
Main Authors: A. E. Nikitin, E. E. Averin, D. E. Rozhkov, A. V. Sozykin, G. A. Procenko
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2020-03-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
atherosclerosis
secondary prevention
cardiovascular disease
target level
low density lipoprotein cholesterol
pcsk9 inhibitors
alirocumab
Online Access:https://www.rpcardio.com/jour/article/view/2123

Internet

https://www.rpcardio.com/jour/article/view/2123

Similar Items